Enthea
Enthea is a U.S. insurance provider that offers employers and unions benefit plans covering psychedelic-assisted therapy, initially Ketamine-Assisted Therapy, with planned expansion to MDMA and psilocybin coverage subject to regulatory approval.
- Company typePrivate
- Founded2019
- HeadquartersNewton, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Enthea does
Enthea is a U.S.-based, venture-backed insurance provider founded in 2019 and headquartered in Newton, Massachusetts. The company designs and distributes employer and union benefit plans that cover psychedelic-assisted therapy, with its initial product focused on Ketamine-Assisted Therapy (KAT). KAT is positioned as a complement to traditional mental health treatment—talk therapy, SSRIs/SNRIs, and lifestyle interventions—and is targeted at treatment-resistant depression, anxiety, and PTSD populations where conventional approaches have produced partial or no response.
The core technical premise is pharmacological rather than digital: ketamine targets NMDA receptors, promotes glutamate release, and is claimed to drive neuroplasticity and rapid symptom relief (often within hours or days of a session), versus the multi-week onset of SSRIs. Enthea's own intellectual property layer is the insurance product and provider network, not the molecule. Disclosed outcomes include a 67% improvement rate in major depressive disorder among Enthea users and 50-70% improvement in treatment-resistant depression patients more broadly, alongside a stated roadmap to cover MDMA- and psilocybin-assisted therapy contingent on FDA approvals.
Enthea operates a B2B enterprise field-sales model, signing employer and union clients directly and delivering care through a curated network of licensed ketamine providers across planned 40 U.S. markets. Revenue is structured as recurring employer-paid insurance premiums, while the underlying KAT unit economics ($400-$800 per session, $2,000-$4,000 per full course) sit with provider partners. As of the most recent data, the company had raised a single $2 million seed round in December 2022 led by Tabula Rasa Ventures (with Mystic Ventures participating) and had not disclosed revenue, ARR, or unit-pricing for its benefit plans. One named enterprise customer, Dr. Bronner's, appears in published case material.
Enthea firmographics
Firmographics- Name
- Enthea
- Website
- https://enthea.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Enthea is a U.S. insurance provider that offers employers and unions benefit plans covering psychedelic-assisted therapy, initially Ketamine-Assisted Therapy, with planned expansion to MDMA and psilocybin coverage subject to regulatory approval.
- Ownership category
- akta.pro rank
Enthea industry classification
Industry- Product category
- Employee Health Benefits Insurance
- NAICS
- Direct Health and Medical Insurance Carriers (524114)
- SIC
- Hospital & Medical Service Plans (6324)
- akta.pro primary industry
- Worksite Hospital Indemnity Insurance (FSAIAMAB)
- akta.pro secondary industry
- Voluntary/Worksite Critical Illness & Hospital Indemnity (Employee-Paid) (FSAIAKAF)
Keywords
Where Enthea is headquartered
LocationHeadquarters
- HQ city
- Newton
- HQ country
- United States
- HQ region
- North America
Markets served
Enthea business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Insurance Premiums from Employers: Enthea provides insurance plans for psychedelic healthcare, charging employers premiums to include ketamine-assisted therapy as a workplace benefit. The company signed several clients with plans to add more, expecting significant employer funding.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Ketamine-Assisted Therapy (KAT) per session |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Enthea product offering
Product offeringCore offering
Enthea provides insurance plans that cover psychedelic-assisted therapy, primarily Ketamine-Assisted Therapy (KAT), as an employee workplace benefit for employers and unions. The company operates a national provider network of licensed ketamine therapy practitioners across U.S. markets, enabling covered employees and union members to access treatment for treatment-resistant depression, anxiety, and PTSD. Initial coverage focuses on ketamine, with planned future expansion to MDMA and psilocybin therapies pending regulatory approval.
Product overview
Enthea offers a suite of insurance products for psychedelic healthcare, with its primary offering being insurance coverage for Ketamine-Assisted Therapy (KAT). The company operates a provider network connecting patients with licensed psychedelic therapy practitioners, and offers employer workplace benefits and union mental health plans. The core product portfolio includes KAT insurance coverage, a psychedelic healthcare provider network, and employer/union benefit packages, with planned future expansion to cover MDMA and psilocybin therapies pending regulatory approval.
Differentiator
Problem solved
Functional benefit
Products and services
- Ketamine-Assisted Therapy (KAT) Insurance Coverage Insurance plans that cover ketamine-assisted psychotherapy as a workplace benefit, providing coverage for treatment-resistant depression, anxiety, PTSD, and other mental health conditions for employees of subscribing employers and union members.
- Psychedelic Healthcare Provider Network Network of licensed healthcare providers offering psychedelic-assisted therapy services, accessible through Enthea's insurance plans for covered employees across U.S. markets.
- Employer Workplace Benefits Plan Insurance product packaged for employers to include psychedelic-assisted therapy coverage as part of their employee workplace benefits, targeting behavioral health conditions including treatment-resistant depression, anxiety, and PTSD.
- Union Mental Health Benefits Plan Insurance plans specifically designed for labor unions to provide psychedelic-assisted therapy benefits to their members as part of union-negotiated health benefits.
Quantifiable outcome
- 67% improvement rate for major depressive disorder conditions
- +2 more outcomes
Companies that use Enthea
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
Enthea technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Enthea partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Enthea competitors and assessment
Company assessmentDirect peers
- Modern Health: Modern Health delivers global mental health benefits to employers through a network of coaches and therapists. It competes for the same employer benefits dollar and could expand into ketamine or psychedelic coverage as clinical evidence matures.
- Spring Health: Spring Health sells precision mental health benefits to employers covering therapy, coaching, and medication. It is a direct competitor in the employer-sponsored mental health benefits category and a likely bundler of psychedelic coverage once approved.
- Lyra Health: Lyra provides mental health benefit plans to employers, including therapy, coaching, and medication management. It competes directly with Enthea for employer mental-health benefit spend and represents the incumbent Enthea must displace in HR buying decisions.
- Cerebral: Cerebral provides online mental health treatment including medication management and has explored ketamine services. It competes with Enthea for employer mental health spend and for the ketamine-assisted therapy patient pool.
Emerging players
- Mindbloom: Mindbloom provides at-home ketamine-assisted therapy protocols, supplying clinical services rather than insurance. It overlaps with Enthea on the demand side for KAT and could become a network provider or a competing coverage enabler.
- Numinus Wellness: Numinus operates psychedelic-assisted therapy clinics and research infrastructure. It overlaps with Enthea as both a potential provider-network partner and a competing clinical delivery channel for insured members.
- Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression. Its clinical progress directly impacts Enthea's planned psilocybin coverage line and represents a critical therapeutic pipeline dependency.
- ATAI Life Sciences: ATAI is a clinical-stage biopharma platform investing in psychedelic mental health therapies including psilocybin, MDMA, and DMT programs. It is a therapeutic counterparty whose pipeline success or failure shapes Enthea's product roadmap.
Broad incumbents
- Evernorth (Cigna): Evernorth, the health services arm of Cigna, administers behavioral health benefits for millions of insured members. It represents the type of incumbent payer Enthea must partner with or compete against as psychedelic coverage normalizes.
- Headspace Health: Headspace Health (the merged Headspace and Ginger entity) offers employer mental health benefits covering therapy, coaching, and self-guided content. It is a broader incumbent in the employer mental health benefits category where Enthea is trying to insert psychedelic coverage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Enthea financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enthea leadership team
Management profileNumber of profiles
Enthea funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enthea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enthea
What does Enthea do?
Enthea provides insurance plans that cover psychedelic-assisted therapy, primarily Ketamine-Assisted Therapy (KAT), as an employee workplace benefit for employers and unions. The company operates a national provider network of licensed ketamine therapy practitioners across U.S. markets, enabling covered employees and union members to access treatment for treatment-resistant depression, anxiety, and PTSD. Initial coverage focuses on ketamine, with planned future expansion to MDMA and psilocybin therapies pending regulatory approval.
Is Enthea a public or private company?
Enthea is a private company. It is classified as venture growth investor backed and is currently operating.
When was Enthea founded?
Enthea was founded in 2019. It employs 11 to 50 people.
Where is Enthea based?
Enthea is headquartered in Newton, United States, in the North America region.
How does Enthea make money?
One revenue line is on record: insurance Premiums from Employers.
Who are Enthea's main competitors?
Direct peers on record are Modern Health, Spring Health, Lyra Health and Cerebral. Emerging players are Mindbloom, Numinus Wellness, Compass Pathways and ATAI Life Sciences. Broad incumbents are Evernorth (Cigna) and Headspace Health.
Does Enthea have an API?
No public API is recorded for Enthea.
What industry is Enthea in?
Enthea's product category is Employee Health Benefits Insurance. Its primary akta.pro industry code is FSAIAMAB, Worksite Hospital Indemnity Insurance, with a secondary code of FSAIAKAF, Voluntary/Worksite Critical Illness & Hospital Indemnity (Employee-Paid). Its NAICS code is 524114 and its SIC code is 6324.